Literature DB >> 17414849

Cholangiocarcinoma: emerging approaches to a challenging cancer.

Tushar Patel1, Pankaj Singh.   

Abstract

PURPOSE OF REVIEW: Cholangiocarcinomas are malignancies arising from biliary tract epithelia that are associated with a poor prognosis. The diagnosis, evaluation and management of these tumors continue to be clinically challenging. In this review, we will discuss recent information that may influence the approach to the diagnosis and management of this devastating tumor. RECENT
FINDINGS: Epidemiological studies are defining patient groups at increased risk of cancer in regions of low prevalence. Emerging approaches that may improve evaluation and management include the potential use of genomic and proteomic markers, cytogenetic and digital image analysis, endoscopic ultrasound with fine needle aspiration, and cholangioscopy. Adoption of aggressive surgical approaches along with the use of preoperative portal vein embolization, hepatic and caudate lobe resection and preoperative laparoscopy may improve survival.
SUMMARY: Recent conceptual and technical advances will impact the clinical approach to cholangiocarcinoma and offer the promise of improving outcomes from this difficult tumor.

Entities:  

Mesh:

Year:  2007        PMID: 17414849     DOI: 10.1097/MOG.0b013e3280495451

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  24 in total

Review 1.  Clinical pathways for pancreatic neuroendocrine tumors.

Authors:  Angela Alistar; Max Sung; Michelle Kim; Randall F Holcombe
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 2.  Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease.

Authors:  Arvind Srinath; Benjamin L Shneider
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-05       Impact factor: 2.839

Review 3.  [Value of laparoscopic liver resection].

Authors:  M R Schön
Journal:  Chirurg       Date:  2010-06       Impact factor: 0.955

4.  Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index.

Authors:  Mirna H Farhat; Ali I Shamseddine; Ayman N Tawil; Ghina Berjawi; Charif Sidani; Wael Shamseddeen; Kassem A Barada
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

5.  Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma.

Authors:  Sun Mi Hong; Chang Wook Park; Hyung Jin Cha; Jung Hee Kwon; Young Sung Yun; Nam Gyu Lee; Dae-Ghon Kim; Hong Gil Nam; Kwan Yong Choi
Journal:  Clin Exp Metastasis       Date:  2012-08-09       Impact factor: 5.150

Review 6.  Imaging of Cholangiocarcinoma.

Authors:  Susann-Cathrin Olthof; Ahmed Othman; Stephan Clasen; Christina Schraml; Konstantin Nikolaou; Malte Bongers
Journal:  Visc Med       Date:  2016-12-06

7.  Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Authors:  F Bernuzzi; F Marabita; A Lleo; M Carbone; M Mirolo; M Marzioni; G Alpini; D Alvaro; K M Boberg; M Locati; G Torzilli; L Rimassa; F Piscaglia; X-S He; C L Bowlus; G-X Yang; M E Gershwin; P Invernizzi
Journal:  Clin Exp Immunol       Date:  2016-05-17       Impact factor: 4.330

8.  Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium.

Authors:  Gregory V Schimizzi; Linda X Jin; Jesse T Davidson; Bradley A Krasnick; Cecilia G Ethun; Timothy M Pawlik; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Sharon M Weber; Ahmed Salem; William G Hawkins; Steven M Strasberg; Maria B Doyle; William C Chapman; Robert C G Martin; Charles Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Ryan C Fields
Journal:  HPB (Oxford)       Date:  2017-11-21       Impact factor: 3.647

9.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

10.  Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.

Authors:  Kawin Leelawat; Siriluck Narong; Wandee Udomchaiprasertkul; Surang Leelawat; Sumalee Tungpradubkul
Journal:  Cancer Cell Int       Date:  2009-01-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.